Ladiratuzumab

Modify Date: 2025-11-29 23:25:10

Ladiratuzumab structure	Common Name	Ladiratuzumab
	CAS Number	1629760-28-6	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Ladiratuzumab

Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer[1][2].

Name	Ladiratuzumab

Description	Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
References	[1]. Trail PA, et al. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol Ther. 2018 Jan;181:126-142. [2]. Li F, et al. Preclinical combinations of the antibody-drug conjugate SGN-LIV1A with chemotherapies show increased activity[J]. Cancer Research, 2016, 76(14_Supplement): 2966-2966.

Description

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

References

[1]. Trail PA, et al. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol Ther. 2018 Jan;181:126-142.

[2]. Li F, et al. Preclinical combinations of the antibody-drug conjugate SGN-LIV1A with chemotherapies show increased activity[J]. Cancer Research, 2016, 76(14_Supplement): 2966-2966.

No Any Chemical & Physical Properties